Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma

Shots:

• The P-III COMBI-AD study involves assessing of Tafinlar (dabrafenib, 150mg, bid) + Mekinist (trametinib, 2mg, qd) vs two PBOs in patients with stage III, BRAF V600E/K-mutant melanoma without prior anticancer therapy for up to 1year
• Results: alive and relapse-free patients @5yrs. (52% vs36%); 49% reduction in risk of relapse or death; m-REF (not reached vs 16.6mos.); DMFS rate (65% vs 54%); @3yrs. OS rate  (86% vs 77%). During the extended follow-up, all patients had completed therapy with no difference in rate or severity of SAEs reported during the follow-up period
• Tafinlar and Mekinist are prescription therapies, used in combination to treat melanoma: that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

Click here ­to­ read full press release/ article | Ref: Novartis | Image: StraitTimes